Hepatitis B: Weighing the costs of treatment

Journal of Gastroenterology and Hepatology (Australia)

Volumn 17, Issue 7, 2002, Pages 737-738

  Angus, Peter W ^a  

^a AUSTIN HEALTH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; HEPATITIS B ANTIBODY; HEPATITIS B(E) ANTIGEN; INTERFERON; LAMIVUDINE;

COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG SAFETY; DRUG USE; EDITORIAL; GENE MUTATION; HEALTH CARE COST; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER CIRRHOSIS; LONG TERM CARE; PRIORITY JOURNAL; PROGNOSIS; RECURRENT DISEASE; SEROCONVERSION; SIDE EFFECT; VIRUS GENE;

EID: 0036065346     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1746.2002.02751.x     Document Type: Editorial

References (7)

1. A multicentre United States Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B
2. Combination low dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against post transplant hepatitis B
3. Chronic hepatitis B
4. The introduction of lamivudine for the treatment of hepatitis B: Expected clinical and economic outcomes based on 4 year clinical trial outcomes
5. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: Results after 3 years of therapy
6. Lamivudine as initial therapy for hepatitis B in the United States
7. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea